CN117551631A - 抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 - Google Patents
抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 Download PDFInfo
- Publication number
- CN117551631A CN117551631A CN202311502816.XA CN202311502816A CN117551631A CN 117551631 A CN117551631 A CN 117551631A CN 202311502816 A CN202311502816 A CN 202311502816A CN 117551631 A CN117551631 A CN 117551631A
- Authority
- CN
- China
- Prior art keywords
- seq
- peptide
- inflammatory
- amino acid
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 220
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 33
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 15
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 15
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 50
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 206010061218 Inflammation Diseases 0.000 claims description 29
- 230000004054 inflammatory process Effects 0.000 claims description 29
- 208000027866 inflammatory disease Diseases 0.000 claims description 21
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 14
- 108010017842 Telomerase Proteins 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 372
- 210000004027 cell Anatomy 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 42
- 150000001413 amino acids Chemical class 0.000 description 39
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 18
- 108700010013 HMGB1 Proteins 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 description 15
- 230000003405 preventing effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 102100037907 High mobility group protein B1 Human genes 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 11
- 101150021904 HMGB1 gene Proteins 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 108010033276 Peptide Fragments Proteins 0.000 description 10
- 102000007079 Peptide Fragments Human genes 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 7
- 108010088535 Pep-1 peptide Proteins 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000000849 HMGB Proteins Human genes 0.000 description 5
- 108010001860 HMGB Proteins Proteins 0.000 description 5
- 102000055207 HMGB1 Human genes 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
- 206010009895 Colitis ischaemic Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 206010016228 Fasciitis Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 241000243985 Onchocerca volvulus Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000025609 Urogenital disease Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 208000003401 eosinophilic granuloma Diseases 0.000 description 2
- 208000001606 epiglottitis Diseases 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 201000008222 ischemic colitis Diseases 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000002042 onchocerciasis Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009290 primary effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 1
- 101710164073 Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091060271 Small temporal RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006329 citrullination Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940044680 immune agonist Drugs 0.000 description 1
- 239000012651 immune agonist Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
Abstract
本发明涉及具有抗炎活性的肽,该肽由选自SEQ ID NO:1~SEQ ID NO:70、SEQ ID NO:72~SEQ ID NO:100、SEQ ID NO:102~SEQ ID NO:128和SEQ ID NO:130~SEQ ID NO:161的一条氨基酸序列构成。本发明还涉及上述肽的编码多核苷酸,以及上述肽在制备抗炎组合物和试剂盒中的应用。
Description
本申请是针对201910110866.0(中国国家申请号)的分案申请。其最初原申请的国际申请号为PCT/EP2013/055326,中国国家申请号为201380038045.1,申请日为2013年3月15日,发明名称为“抗炎性肽及包含其的组合物”。于2019年2月12日递交了针对该申请(201380038045.1)的中国国家申请号为201910110866.0的分案申请,发明名称为“抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用”。
技术领域
本发明涉及抗炎性肽及包含该抗炎性肽的组合物。
背景技术
炎症是一种生物防御,作为保护身体不受到可能由外部物理刺激、化学刺激(例如暴露在多种过敏原下)或包括细菌、真菌及病毒在内的微生物的入侵造成的对生物组织的损伤的手段。
产生前列腺素、血栓素等的环氧合酶(COX)途径或脂氧合酶(LOX)途径可用来进行炎症信号传递。一旦炎症信号被传递,身体所发生的诸多改变之一是血管扩张,以增加炎症周边的血液供给,从而集中炎症应答所需的血细胞,例如嗜中性粒细胞。然而,当异常的生物防御应答过多地发生时,可能导致炎性疾病。为了防止这种情况,目前正在开发通过抑制炎症信号传导途径中所用的酶(例如,COX-1、COX-2、5-LOX、12-LOX等)来抑制过度的炎症应答的药物。
根据应答时间,炎症可分为急性炎症(即时应答,非特异性应答,数天至数周)、慢性炎症(延迟的应答,特异性应答,数周或更久)、亚急性炎症(急性炎症与慢性炎症之间的中间阶段,特征在于单核及多形核的混合产物)。
并且,除了肽因子之外,诸如前列腺素、白三烯、脂质因子(包括血小板活化因子(PAF))、炎症因子的合成酶、自由基(例如NO(一氧化氮))、多种细胞粘着分子、免疫系统及凝血因子等因子皆可引起炎症。
一旦细胞因已知的致炎症物质(例如外部生物因子(微生物、病毒、寄生虫)、物理因子(机械刺激、热、辐射、电)及化学因子)而受损时,会释放出组胺及激肽。释出的组胺及激肽将造成血管扩张、毛细血管通透性增加及炎症处的巨噬细胞集中,并引起血液流速增加、水肿、免疫细胞及抗体的迁移、疼痛以及发热。
目前使用的炎症治疗物为合成药物(例如布洛芬)、抗组胺剂、类固醇、可的松、免疫抑制剂和免疫激动剂;但这些药物仅暂时性地缓解炎症。这些药物无法从根本上治疗炎症,且具有诸如超敏反应和免疫系统退化等副作用。
因此,为了有效缓解炎症,已进行了开发抑制上述炎症蛋白的表达的物质的研究。然而,先前开发的抗炎物质具有若干问题。已开发出了包括非类固醇类抗炎药物(NSAID)及类固醇类抗炎药物(SAID)在内的多种类型的抗炎药物;但这些药物不但时常在服用时产生副作用,而且它们无法从根本上治愈炎症。因此,目前需要在物质上及经济上皆可行的抗炎药物。就急性或慢性炎症(例如慢性类风湿性关节炎)方面的一个例子而言,非类固醇类抗炎药物不仅会抑制COX-2酶的活性,已知它们还会抑制COX-1的活性,从而引起例如胃肠道失调等副作用。
本发明人发现,源自端粒酶的肽可具有抗炎性质,由此完成了本发明。
因此,本发明的目的在于提供一种新颖的肽。
本发明的另一个目的在于提供编码该新颖的肽的多核苷酸。
本发明的另一个目的在于提供一种具有抗炎活性的肽。
本发明的另一个目的在于提供使用此肽作为活性成分的抗炎组合物。
本发明的另一个目的在于提供使用此肽作为活性成分的化妆品组合物。
本发明的另一个目的在于提供使用此肽作为活性成分的药物组合物。
发明内容
本发明的一个实施方式涉及一种具有抗炎活性的肽,其中该肽包含SEQ ID NO:1~161中的至少一个氨基酸序列,或其中该肽与上述序列具有至少80%的序列同一性,或者该肽为上述肽的片段。
在另一个实施方式中,上述片段由3个或更多个氨基酸组成。举例而言,所述片段可由4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25或26个氨基酸残基组成。
在另一个实施方式中,上述肽由30个或更少个氨基酸组成。举例而言,所述肽可由29、28、27、26、25、24、23、22、21、20、19、18、17、16、15、14、13、12、11、10、9或8个氨基酸残基组成。
在另一个实施方式中,上述肽由SEQ ID NO:1~161中的任一个氨基酸序列组成。
在另一个实施方式中,上述肽包含选自由以下序列组成的组的任一个氨基酸序列:SEQ ID NO:1~SEQ ID NO:6、SEQ ID NO:9、SEQ ID NO:11、SEQ ID NO:14~21、SEQ IDNO:23~SEQ ID NO:37、SEQ ID NO:39~SEQ ID NO:44、SEQ ID NO:47~SEQ ID NO:53、SEQID NO:55~SEQ ID NO:61、SEQ ID NO:63~SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:94、SEQ ID NO:96、SEQ ID NO:99~SEQ ID NO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ IDNO:115、SEQ ID NO:116、SEQ ID NO:120~SEQ ID NO:122、SEQ ID NO:124、SEQ ID NO:129~SEQ ID NO:133、SEQ ID NO:142~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQID NO:149和SEQ ID NO:155~SEQ ID NO:159。
在另一个实施方式中,上述肽包含选自由以下序列组成的组的任一个氨基酸序列:SEQ ID NO:15~SEQ ID NO:18、SEQ ID NO:23~SEQ ID NO:27、SEQ ID NO:29、SEQ IDNO:31~SEQ ID NO:34、SEQ ID NO:39~SEQ ID NO:41、SEQ ID NO:47、SEQ ID NO:48、SEQID NO:51~SEQ ID NO:53、SEQ ID NO:55~SEQ ID NO:58、SEQ ID NO:61、SEQ ID NO:65~SEQ ID NO:68、SEQ ID NO:70、SEQ ID NO:73~SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:87、SEQ ID NO:90~SEQ ID NO:94、SEQ ID NO:96、SEQ IDNO:99、SEQ ID NO:101~SEQ ID NO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ ID NO:120、SEQ ID NO:121、SEQ ID NO:129~SEQ ID NO:132、SEQ ID NO:142~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149和SEQ ID NO:157~SEQ ID NO:159。
在另一个实施方式中,上述肽包含选自由以下序列组成的组的任一个氨基酸序列:SEQ ID NO:1~SEQ ID NO:5、SEQ ID NO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ ID NO:17~SEQ ID NO:27、SEQ ID NO:29、SEQ IDNO:30、SEQ ID NO:32~SEQ ID NO:53、SEQ ID NO:55~SEQ ID NO:60、SEQ ID NO:67、SEQID NO:68、SEQ ID NO:70、SEQ ID NO:72~SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:92、SEQ ID NO:94、SEQ ID NO:99~SEQ ID NO:112、SEQ ID NO:114、SEQ ID NO:127~SEQ IDNO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149、SEQ ID NO:151和SEQ ID NO:153~SEQ ID NO:161。
在另一个实施方式中,上述肽包含选自由以下序列组成的组的任一个氨基酸序列:SEQ ID NO:1~SEQ ID NO:5、SEQ ID NO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ ID NO:17~SEQ ID NO:23、SEQ ID NO:25~SEQ IDNO:27、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:33~SEQ ID NO:43、SEQ ID NO:156、SEQID NO:157和SEQ ID NO:159。
在另一个实施方式中,上述肽包含选自由以下序列组成的组的任一个氨基酸序列:SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:4、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:20、SEQ ID NO:22、SEQ ID NO:23、SEQ ID NO:24、SEQ ID NO:25、SEQ ID NO:26、SEQ ID NO:27、SEQ ID NO:28、SEQ ID NO:29、SEQ ID NO:30、SEQ IDNO:33、SEQ ID NO:34、SEQ ID NO:35、SEQ ID NO:36、SEQ ID NO:37、SEQ ID NO:38、SEQ IDNO:39、SEQ ID NO:40、SEQ ID NO:41、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:45、SEQ IDNO:52、SEQ ID NO:57、SEQ ID NO:60、SEQ ID NO:61、SEQ ID NO:62、SEQ ID NO:64、SEQ IDNO:65、SEQ ID NO:67、SEQ ID NO:68、SEQ ID NO:69、SEQ ID NO:91、SEQ ID NO:99、SEQ IDNO:100、SEQ ID NO:104、SEQ ID NO:106、SEQ ID NO:107、SEQ ID NO:108、SEQ ID NO:109、SEQ ID NO:111、SEQ ID NO:112、SEQ ID NO:115、SEQ ID NO:117、SEQ ID NO:118、SEQ IDNO:119、SEQ ID NO:120、SEQ ID NO:122、SEQ ID NO:124、SEQ ID NO:125、SEQ ID NO:126、SEQ ID NO:129、SEQ ID NO:130、SEQ ID NO:131、SEQ ID NO:132、SEQ ID NO:135、SEQ IDNO:146、SEQ ID NO:151、SEQ ID NO:154和SEQ ID NO:156。
在另一个实施方式中,上述肽源自人类端粒酶。
在本发明的一个实施方式中,提供了一种编码具有抗炎活性的肽的多核苷酸,其中该肽包含SEQ ID NO:1~161中的至少一个氨基酸序列,或该肽与上述序列具有至少80%的序列同一性,或该肽为上述肽的片段。
在所述多核苷酸的另一个实施方式中,上述肽由30个或更少个氨基酸组成。举例而言,上述肽可由29、28、27、26、25、24、23、22、21、20、19、18、17、16、15、14、13、12、11、10、9或8个氨基酸残基组成。
在所述多核苷酸的另一个实施方式中,上述肽由SEQ ID NO:1~161中的任一个氨基酸序列组成。
在所述多核苷酸的另一个实施方式中,上述肽源自人类端粒酶。
在本发明的一个实施方式中,提供了一种包含肽作为活性成分的抗炎组合物,其中,该肽包含SEQ ID NO:1~161中的至少一个氨基酸序列,该肽的氨基酸序列与上述序列的同源性超过80%,或该肽为上述肽的片段。
在所述组合物的另一个实施方式中,上述肽由30个或更少个氨基酸组成,参照上文。
在所述组合物的另一个实施方式中,上述肽由SEQ ID NO:1~161中的任一个氨基酸序列组成。
在所述组合物的另一个实施方式中,上述肽源自人类端粒酶。
在所述组合物的另一个实施方式中,上述组合物用于治疗或预防炎性疾病。
在所述组合物的另一个实施方式中,上述组合物为用于改善或防止皮肤炎症的化妆品组合物。
在所述组合物的另一个实施方式中,上述组合物为用于治疗或预防炎性疾病的药物组合物。
在所述组合物的另一个实施方式中,上述组合物为用于治疗或预防炎症的食品组合物。
在所述组合物的另一个实施方式中,上述炎性疾病的特征在于其选自由下列疾病组成的组:(1)普遍的或局部的炎性疾病(例如,过敏症;免疫复合物病;枯草热;超敏性休克;内毒素性休克;恶病质,过热;肉芽肿病;或结节病);(2)胃肠相关疾病(例如,阑尾炎;胃溃疡;十二指肠溃疡;腹膜炎;胰腺炎;溃疡性结肠炎、急性结肠炎或缺血性结肠炎;胆管炎;胆囊炎、脂肪泻、肝炎、克罗恩氏病(Crone’s disease);或惠普尔氏病(Whipple’sDisease));(3)皮肤相关疾病(例如,牛皮癣;烧伤;晒伤;皮肤炎;荨麻疹性疣或风团);(4)血管相关疾病(例如,脉管炎(angiitis);血管炎(vasculitis);心内膜炎;动脉炎;动脉硬化;血栓性静脉炎;心包炎;充血性心力衰竭;心肌炎;心肌缺血;结节性动脉周围炎;周期性狭窄(recurrent stenosis);柏格氏病(Buerger'sdisease);或风湿热);(5)呼吸道疾病(例如,哮喘;会厌炎;支气管炎;肺气肿;鼻炎;囊性纤维化;间质性肺炎;COPD(慢性阻塞性肺病);成人呼吸窘迫综合征;粉尘病;肺泡炎;细支气管炎;咽炎;肋膜炎;或鼻窦炎);(6)骨胳、关节、肌肉及结缔组织相关疾病(例如,嗜伊红性肉芽肿;关节炎;关节痛;骨髓炎;皮肌炎;筋膜炎;佩吉特氏病(Paget's disease);痛风;牙周病;类风湿性关节炎;重症肌无力;强直性脊柱炎;或滑膜炎);(7)泌尿生殖系统失调(例如,附睪炎;阴道炎;前列腺炎;或尿道炎);(8)中枢或周围神经系统相关疾病(例如,阿尔茨海默氏病;脑膜炎;脑炎;多发性硬化症;脑梗死;脑栓塞;格-巴二氏综合征(Guillain-Barre syndrome);神经炎;神经痛;脊柱损伤;麻痹;或葡萄膜炎);(9)病毒(例如,流行性感冒;呼吸道合胞病毒;HIV;乙型肝炎;丙型肝炎;或疱疹病毒)、感染性疾病(例如,登革热;或败血症)、真菌感染(例如,念珠菌病);或细菌、寄生虫及类似微生物感染(例如,弥散性菌血症;疟疾;盘尾丝虫病;或阿米巴病);(10)自身免疫病(例如,甲状腺炎;红斑狼疮;古德帕斯丘综合征(Goodpasture'ssyndrome);同种异体移植排斥;移植物抗宿主病;或糖尿病);及(11)癌症或肿瘤疾病(例如,霍奇金病)。
在本发明的一个实施方式中,提供了一种通过施用所述抗炎组合物来治疗或防止炎性疾病的方法。
在本发明的一个实施方式中,提供了一种用于预防或治疗炎性疾病的试剂盒,其包含:具有抗炎活性的肽或包含所述肽的组合物,其中,该肽包含SEQ ID NO:1~161中的至少一个氨基酸序列,该肽与上述序列具有超过80%的同源性,或该肽为上述肽的片段;以及包括该肽或组合物的施用剂量、施用途径、施用频率及适应证中的至少一种的使用说明书。
产业实用性
根据本发明,序列为SEQ ID NO:1~161的肽在抑制炎症及预防性手段方面皆具有优异的功效。因此,包含本发明的肽的组合物可用作抗炎药物组合物或用作化妆品组合物,进而可治疗或防止多种不同类型的炎性疾病。
参考文献
KR2012-0130996A
KR2012-0133661A
KR2011-0060940A
US2011-0150873A1
Bonaldi T等,EMBO J,(22)5551-60,2003
Yankner BA等,Science(New York,N.Y.)[1990,250(4978):279-282]
Dahlgren KN等,J.Biol.Chem.277:32046-32053,2002.
附图说明
图1~图16是对单核细胞(monocyte)的TNF-α抑制效果的筛选结果。
图17~图35是对细胞系THP-1的TNF-α抑制效果的筛选结果。
图36~图108是显示出HMGB1在细胞中积累的选定的肽的蛋白质印迹结果。
具体实施方式
由于本发明可适应各种转化形式及实际应用实例,以下是对本发明的更详细描述。然而,这不意味着对实际应用形式的限制;应理解的是,本发明的意图在于包括所有转化形式、等价形式及替代形式中的技术概念及外延。在描述本发明时,若有关现有技术的任何详细描述被认为会破坏本发明的基本原理,则将略去该描述。
已知端粒为染色体末端的遗传物质重复序列,其防止染色体受损或与其它染色体融合。端粒的长度会在每次细胞分裂时缩短,在细胞分裂一定次数后,端粒的长度会缩得非常短以使细胞停止分裂并死亡。另一方面,已知端粒的延长可延长细胞的寿命。举例而言,癌细胞分泌一种称为端粒酶的酶,其防止端粒缩短,因而导致癌细胞的增殖。本发明是基于发现具有抗炎效果的源自端粒酶的肽而完成的。
在本发明的一个实施方式中,提供了一种具有抗炎活性的肽。所述肽包含SEQ IDNO:1~161中的至少一个氨基酸序列,所述肽与上述序列具有超过80%的同源性,或所述肽为上述肽的片段。
SEQ ID NO:1~161中描述的肽如下表1所示。SEQ ID NO:162列出了人类端粒酶蛋白的全长序列。SEQ ID NO:163列出了由16个氨基酸的序列构成的源自端粒酶的肽。
下表1中的“名称”用于区分这些肽。在本发明的另一个具体实施方式中,SEQ IDNO:1~161中所述的肽中有多于一种肽包括“合成肽”,即端粒酶的选定区域的合成肽。在本说明书中,术语“pep”是指:具有SEQ ID NO:1~161中任一个的肽、或包含与上述序列的同源性超过80%的氨基酸序列的肽、或上述肽的肽片段。
表1
在本发明的一个实施方式中,提供了一种编码具有抗炎活性的肽的多核苷酸。该多核苷酸编码:包含SEQ ID NO:1~161中的至少一个氨基酸序列的肽、与上述序列具有超过80%同源性的肽、或为上述肽的片段的肽。上述多核苷酸使得能够大量制造该肽。例如,培养包括编码肽的多核苷酸的载体可容许大量制造该肽。
本文所公开的肽可包括:包含同源性超过80%、超过85%、超过90%、超过95%、超过96%、超过97%、超过98%或超过99%的氨基酸序列的肽。并且,本发明所公开的肽可包括:包含SEQ ID NO:1或其片段的肽,和具有超过1个转变的(transformed)氨基酸、超过2个转变的氨基酸、超过3个转变的氨基酸、超过4个转变的氨基酸、超过5个转变的氨基酸、超过6个转变的氨基酸或超过7个转变的氨基酸的肽。
在本说明书及权利要求书中,术语「同源性」及「序列同一性」可互换使用,以指示两条氨基酸(或核酸,如果有关的话)序列之间的序列重叠程度。
除非另有说明,本文针对肽所用的术语「序列同一性」指的是按(nref-ndif)·100/nref计算的序列同一性,其中ndif是指当比对两个序列以使得相同的氨基酸数目最大时这两个序列中不相同的残基的数目,其中nref是指这些序列中最短的那个的残基数。因此,DNA序列agtcagtc与序列aatcaatc将具有75%的序列同一性(ndif=2且nref=8)。
在一些实施方式中,通过常规方法来确定序列同一性,例如:Smith和Waterman,1981,Adv.Appl.Math.2:482;通过相似度寻找法(Pearson和Lipman,1988,Proc.Natl.Acad.Sci.USA 85:2444);使用CLUSTAL W算法(Thompson等,1994,NucleicAcids Res 22:467380);利用计算机执行这些算法(Wisconsin Genetics SoftwarePackage,Genetics Computer Group中的GAP、BESTFIT、FASTA及TFASTA)。也可使用BLAST算法(Altschul等,1990,Mol.Biol.215:403-10),其软件可通过美国国家生物技术信息中心(www.ncbi.nlm.nih.gov/)获得。当使用任何上述算法时,使用「视窗(Window)」长度、空位罚分等的缺省参数。
在本发明的一个实施方式中,氨基酸序列的改变属于对肽的物理和化学特性的修改。例如,可针对提高肽的热稳定性、改变底物特异性和改变最适pH来进行氨基酸转变(transformation)。
在本发明的一个实施方式中,包含SEQ ID NO:1~161中的至少一个的氨基酸序列的肽、包含与上述序列具有超过80%的同源性的氨基酸序列的肽、或上述肽的肽片段优选由30个或更少个氨基酸组成。
在本发明的一个实施方式中,包含SEQ ID NO:1~161中的至少一个的氨基酸序列的肽、包含与上述序列具有超过80%的同源性的氨基酸序列的肽、或上述肽的肽片段包含源自端粒酶(更具体而言,智人(Homo sapiens)的端粒酶)的肽。
本文的术语「氨基酸」不仅包括天然整合成肽的22种标准氨基酸,也包括D-异构物及转变的氨基酸。因此,在本发明的特定实施方式中,本文的肽包括具有D-氨基酸的肽。另一方面,肽可包括非标准氨基酸,例如那些经翻译后修饰的氨基酸。翻译后修饰的例子包括磷酸化、糖基化、酰化(包括乙酰化、肉豆蔻酰化、棕榈酰化)、烷基化、羧基化、羟基化、糖化、生物素化、泛素化、化学性质转变(例如,β-消除脱酰亚胺作用、脱酰胺作用)及结构转变(例如,二硫键形成)。此外,也包括氨基酸的改变,氨基酸发生改变归因于在以用于形成肽缀合物的交联剂进行的结合过程中的化学反应。
本文所公开的肽可以是已从天然来源鉴定并分离出的野生型肽。另一方面,当与SEQ ID NO:1的肽片段比较时,本文所公开的肽可以是包含一个或多个替换、缺失和/或插入的氨基酸的人工突变肽。野生型多肽中(不仅在人工突变肽中)的氨基酸变动包括不影响蛋白折叠和/或活化的保守性氨基酸替换。保守性替换的例子属于由以下氨基酸组成的组:碱性氨基酸(精氨酸、赖氨酸及组氨酸)、酸性氨基酸(谷氨酸及天冬氨酸)、极性氨基酸(谷氨酰胺及天冬酰胺)、疏水性氨基酸(亮氨酸、异亮氨酸、缬氨酸及甲硫氨酸)、芳香族氨基酸(苯丙氨酸、色氨酸及酪氨酸)和小型氨基酸(甘氨酸、丙氨酸、丝氨酸及苏氨酸)。通常不会改变特定活性的氨基酸替换已为本发明所属技术领域所知。最常发生的改变为Ala/Ser、Val/Ile、Asp/Glu、Thr/Ser、Ala/Gly、Ala/Thr、Ser/Asn、Ala/Val、Ser/Gly、Tyr/Phe、Ala/Pro、Lys/Arg、Asp/Asn、Leu/Ile、Leu/Val、Ala/Glu、Asp/Gly,以及相反的改变。保守性替换的其他实例示于下表2中。
表2
通过选择在下列功效方面显著不同的替换来进行肽的生物性质的实质性转变:(a)在替换区域中维持多肽主干的结构(例如折叠片或螺旋三维结构)的功效;(b)维持目标区域中的分子的电荷或疏水性的功效;或(c)维持侧链体积的功效。天然残基可通过一般的侧链性质而分为以下组:
(1)疏水性:正亮氨酸、met、ala、val、leu、ile;
(2)中性亲水性:cys、ser、thr;
(3)酸性:asp、glu;
(4)碱性:asn、gln、his、lys、arg;
(5)影响链取向的残基:gly、pro;和
(6)芳香性:trp、tyr、phe。
可通过将上述类别的成员换成另一类别来进行非保守性替换。与维持肽的正确的三维结构无关的任何半胱氨酸残基通常都可以替换为丝氨酸,因而增加了分子的氧化稳定性并预防了不正确的交联。相反地,可通过将(多个)半胱氨酸键加入肽中来增进稳定性。
肽的氨基酸变异的其他类型是抗体糖基化模式的改变。此处的术语「改变」是指碳水化合物残基的缺失和/或增加肽中不存在的至少一个糖基化残基。
肽中的糖基化通常为N-连接型或O-连接型糖基化。本文的术语「N-连接型」是指碳水化合物残基接附至天冬酰胺残基的侧链上。作为三肽序列,天冬酰胺-X-丝氨酸及天冬酰胺-X-苏氨酸(其中X为除了脯氨酸之外的任何氨基酸)为碳水化合物残基经由酶作用而附接至天冬酰胺侧链的识别序列。因此,使一条这种三肽序列存在于多肽中,便产生了潜在的糖基化位置。「O-连接型糖基化」意指将糖N-乙酰半乳糖胺、半乳糖或木糖中的一种附接至羟基氨基酸上。最常见的羟基氨基酸为丝氨酸或苏氨酸,但也可使用5-羟基脯氨酸或5-羟基赖氨酸。
通过改变氨基酸序列以含有上述三肽序列来将糖基化位点方便地加入肽中(以获得N-连接型糖基化位点)。这些改变可以通过将至少一个丝氨酸或苏氨酸残基加入第一抗体序列中或通过用这些残基进行替换来完成(以获得O-连接型糖基化位点)。
在本发明的一个实施方式中,多核苷酸为核酸分子,其可为单链或双链的、天然的或人工的DNA或RNA分子。核酸分子可为相同类型的一个或多个核酸(例如,具有相同的核苷酸序列),或为不同类型的核酸。核酸分子包含一种或多种DNA、cDNA、诱骗(decoy)DNA、RNA、siRNA、miRNA shRNA、stRNA、snoRNA、snRNA PNA、反意寡聚物、质粒及其它经修饰的核酸,但不限于此。
已知HMGB1蛋白为细胞因子。其先经历乙酰化,并因外部刺激而移位至细胞质中。随后其被分泌至细胞外,因而扮演着致炎性细胞因子的角色。因为当此活性引起炎症时,HMGB1蛋白被分泌至细胞外,且炎性疾病(例如Churg strauss综合征、类风湿性关节炎和舍格伦综合征(Sjogren’s syndrome))患者将呈现出升高的HMGB1血清水平。因此,如果即使在致炎刺激物存在时细胞核仍含有大量的HMGB1,则揭示了HMGB1未被分泌至细胞外的事实,这意味着炎症受到了抑制。
在本发明的一个实施方式中,当用包含SEQ ID NO:1~161中的任一个氨基酸序列的肽处理细胞、用具有与上述序列的同源性超过80%的氨基酸序列的肽处理细胞、或用上述肽的片段处理细胞时,细胞核内的HMGB1量会增加。这代表上述肽具有卓越的炎症预防或抑制功效。
并且,在本发明的特定实施方式中,包含SEQ ID NO:1~161中的任一个氨基酸序列的肽、具有与上述序列的同源性超过80%的氨基酸序列的肽、或上述肽的片段具有以下优点:因为在细胞内的毒性低,其具有高度可行性。
在本发明中,「炎性疾病」是宽泛的适应证,其指以炎症为主因的任何疾病或由疾病造成的炎症。具体而言,炎性疾病包括:(1)普遍的或局部的炎性疾病(例如,过敏症;免疫复合物病;枯草热;超敏性休克;内毒素性休克;恶病质、过热;肉芽肿病;或结节病);(2)胃肠相关疾病(例如,阑尾炎;胃溃疡;十二指肠溃疡;腹膜炎;胰腺炎;溃疡性结肠炎、急性结肠炎或缺血性结肠炎;胆管炎;胆囊炎、脂肪泻、肝炎、克罗恩氏病;或惠普尔氏病);(3)皮肤相关疾病(例如,牛皮癣;烧伤;晒伤;皮肤炎;荨麻疹性疣或风团);(4)血管相关疾病(例如,脉管炎;血管炎;心内膜炎;动脉炎;动脉硬化;血栓性静脉炎;心包炎;充血性心力衰竭;心肌炎;心肌缺血;结节性动脉周围炎;周期性狭窄;柏格氏病;或风湿热);(5)呼吸道疾病(例如,哮喘;会厌炎;支气管炎;肺气肿;鼻炎;囊性纤维化;间质性肺炎;COPD(慢性阻塞性肺病);成人呼吸窘迫综合征;粉尘病;肺泡炎;细支气管炎;咽炎;肋膜炎;或鼻窦炎);(6)骨胳、关节、肌肉及结缔组织相关疾病(例如,嗜伊红性肉芽肿;关节炎;关节痛;骨髓炎;皮肌炎;筋膜炎;佩吉特氏病;痛风;牙周病;类风湿性关节炎;重症肌无力;强直性脊柱炎;或滑膜炎);(7)泌尿生殖系统失调(例如,附睪炎;阴道炎;前列腺炎;或尿道炎);(8)中枢或周围神经系统相关疾病(例如,阿尔茨海默氏病;脑膜炎;脑炎;多发性硬化症;脑梗死;脑栓塞;格-巴二氏综合征;神经炎;神经痛;脊柱损伤;麻痹;或葡萄膜炎);(9)病毒(例如,流行性感冒;呼吸道合胞病毒;HIV;乙型肝炎;丙型肝炎;或疱疹病毒)、感染性疾病(例如,登革热;或败血症)、真菌感染(例如,念珠菌病);或细菌、寄生虫及类似微生物感染(例如,弥散性菌血症;疟疾;盘尾丝虫病;或阿米巴病);(10)自身免疫病(例如,甲状腺炎;红斑狼疮;古德帕斯丘综合征;同种异体移植排斥;移植物抗宿主病;或糖尿病);及(11)癌症或肿瘤疾病(例如,霍奇金病),但不限于此。
数十年来,治疗这些疾病的炎性组分已成为全球制药工业的主要目标,并且已开发出多种有用的治疗剂。例子包括皮质类固醇(被设计用来模拟皮质醇的效果的多种天然的、半合成的及合成的药剂,包括泼尼松龙、甲基泼尼松龙(methylprednisolone)、地塞米松、倍他米松、氟替卡松等)、环氧合酶抑制剂(非选择性抑制剂或cox-1选择性抑制剂,例如吲哚美辛、柳氮磺胺吡啶(sulfasalzine)及阿司匹林,以及近来的cox-2选择性抑制剂,例如塞来考昔)、白三烯阻断剂(例如孟鲁司特)及抗-TNF(例如经修饰的单克隆中和抗体,包括英夫利昔单抗(RemicadeTM)和阿达木单抗(HumiraTM);TNF受体融合蛋白,例如依那西普(EnbrelTM);以及小分子TNF-α合成抑制剂,例如沙立度胺)。
在本发明的一个实施方式中,提供了一种包含肽作为活性成分的抗炎组合物。所述肽包含SEQ ID NO:1~161中的至少一个氨基酸序列,所述肽与上述序列具有超过80%的同源性,或所述肽为上述肽的片段。
在本发明的一个实施方式中,抗炎组合物可含有0.1μg/mg至1mg/mg、特别是1μg/mg至0.5mg/mg、更特别是10μg/mg至0.1mg/mg的包含SEQ ID NO:1~161中的至少一个的氨基酸序列的肽、包含与上述序列具有超过80%的同源性的氨基酸序列的肽、或上述肽的肽片段。当含有上述范围内的肽时,该组合物的所有安全性及稳定性均可得到满足,且就成本效益而言为适当的。
在本发明的一个实施方式中,所述组合物可应用于所有动物,包括人、狗、鸡、猪、牛、羊、豚鼠及猴。
在本发明的一个实施方式中,提供了用于以活性成分治疗或预防炎性疾病的药物组合物,所述活性成分由以下肽组成:由来自SEQ ID NO:1~161的氨基酸序列构成的肽,包含与上述序列具有超过80%的同源性的氨基酸序列的肽,或SEQ ID NO:1的肽片段。在本发明的一个实施方式中,所述药物组合物可以通过口服、直肠、经皮、静脉内、肌肉内、腹膜内、骨髓内、硬膜外或皮下方式来施用。
口服施用的形式可以是(但不限于)片剂、丸剂、软胶囊或硬胶囊、颗粒剂、粉末、溶液或乳液。非口服施用的形式可以是(但不限于)注射剂、滴剂、洗剂、软膏、凝胶、乳膏、悬浮液、乳液、栓剂、贴片或喷雾剂。
在本发明的一个实施方式中,若有需要的话,药物组合物可含有添加剂,例如稀释剂、赋形剂、润滑剂、粘合剂、崩解剂、缓冲剂、分散剂、表面活性剂、着色剂、芳香剂或甜味剂。在本发明的一个实施方式中,药物组合物可以用本领域的常规工业方法来制造。
在本发明的一个实施方式中,药物组合物的活性成分可根据患者的年龄、性别、体重、病理及状态、施用途径或处方医师的判断而有所变化。本领域技术人员可基于这些因素来确定剂量,举例而言,每日剂量可以是(但不限于)0.1μg/kg/日至1g/kg/日,特别是1μg/kg/日至10mg/kg/日,更特别是10μg/kg/日至1mg/kg/日,更特别是50μg/kg/日至100μg/kg/日。在本发明的一个实施方式中,可以(但不限于)每日施用1至3次所述药物组合物。
在本发明的一个实施方式中,提供了一种用于改善或防止皮肤炎症的皮肤外用组合物。所述皮肤外用组合物可含有以下活性成分:包含来自SEQ ID NO:1~161的氨基酸序列的肽,包含与上述序列具有超过80%的同源性的氨基酸序列的肽,或上述肽的肽片段。
在本发明的另一个实施方式中,提供了一种用于改善或防止皮肤炎症的化妆品组合物。所述化妆品组合物可含有以下活性成分:包含来自SEQ ID NO:1~161的氨基酸序列的肽,包含与上述序列具有超过80%的同源性的氨基酸序列的肽,或上述肽的肽片段。
在本发明的一个实施方式中,可以以所有适于局部应用的形式提供外用组合物或化妆品组合物。例如,可提供溶液、通过将油相分散于水中而获得的乳液、通过将水分散于油相中而获得的乳液、悬浮液、固体、凝胶、粉末、糊剂、泡沫或气溶胶等形式。这些形式可用本领域的常规工业方法来制造。
在本发明的一个实施方式中,在无损于主要效果的程度内,化妆品组合物可包含能够理想地增加主要效果的其它成分。在本发明的一个实施方式中,化妆品组合物可额外包含:保湿剂、软化剂、表面活性剂、UV吸收剂、防腐剂、杀真菌剂、抗氧化剂、pH调节剂、有机或无机色素、芳香剂、冷却剂或止汗剂。本领域技术人员可在无损本发明的目的及效果的程度内决定上述成份的配制比例,且基于化妆品组合物的总重量的配制比例可以为0.01重量%至5重量%,特别是0.01重量%至3重量%。
在本发明的一个实施方式中,提供了一种用于预防或抑制炎症的食品组合物。所述食品组合物可含有以下活性成分:包含来自SEQ ID NO:1~161的氨基酸序列的肽、包含与上述序列具有超过80%的同源性的氨基酸序列的肽、或上述肽的肽片段。
在本发明的一个实施方式中,食品组合物的形式不限,而可以是例如颗粒、粉末、液体及固体形式。除了活性成分之外,每种形式都可以用由本领域技术人员适当选择的工业常用成分来形成,并且能够与其它成分一起增加效果。
本领域技术人员可决定上述活性成分的剂量,且每日剂量可以是例如1μg/kg/日至10mg/kg/日,更特别是10μg/kg/日至1mg/kg/日,更特别是50μg/kg/日至100μg/kg/日,但不限于这些数量,并且可依照年龄、健康状态、并发症及其它多种因素而有所变化。
在本发明的一个实施方式中,提供了用包含来自SEQ ID NO:1~161的氨基酸序列的肽、包含与上述序列具有超过80%的同源性的氨基酸序列的肽、或上述肽的肽片段来预防或治疗炎性疾病的用途。
在本发明的一个实施方式中,提供了一种通过将上述肽应用至患者来预防或治疗炎性疾病的方法。
在本发明的一个实施方式中,提供了一种用于预防或治疗炎性疾病的试剂盒。该试剂盒可以包含:具有抗炎活性的肽或包含该肽的组合物,其中,所述肽包含SEQ IDNO:1~161中的任一个氨基酸序列,所述肽与上述序列具有超过80%以上的同源性,或者所述肽为上述肽的片段;以及包括该肽或组合物的施用剂量、施用途径、施用频率及适应证中的至少一种的使用说明书。
本文所用的术语意在用来描述实施方式,而非限制本发明。前面没有数字的术语并非用来限制量,而是用来表示所用术语所指的事物可以超过一个。术语「包括」、「具有」、「由……构成」及「包含」应作开放性解释(即,「包括但不限于」)。
提及数值范围是用来代替陈述该范围内的单独的数字,因此,除非明确指明,每个数字都可被解读为其中集合的单独的数字。所有范围的端值都包括在该范围内,且可以独立地组合。
除非在上下文中有另外注明或明显矛盾,否则本文所述的所有方法都可以以合适的顺序进行。除非包括在权利要求中,否则任一个实施方式及所有实施方式或示例性语言(如使用「例如」的语言)的使用是为了更清楚地描述本发明,而非限制本发明的范围。本文中,权利要求书以外的任何语言都不应被解读为本发明的必需要素。除非另有定义,本文所用的科技术语具有本发明所属领域的技术人员所通常理解的意义。
本发明的优选实施方式是本发明人已知的用于实施本发明的最佳模式。在阅读之前的描述后,优选实施方式的变化形式对本领域技术人员而言将是清楚的。本发明人希望本领域技术人员可充分使用这些变化形式,且本发明可以以本文所列方式以外的其它方式来实施。因此,在专利法允许下,本发明包括所附权利要求中所述的发明的关键点的等价形式及其变化形式。此外,除非上下文中另有明确陈述或矛盾,否则上述组成部分的任何组合情况中的所有可能的变化形式皆包括在本发明中。尽管通过示例性实施方式说明并示出了本发明,但本领域技术人员将充分理解,在不悖离权利要求所限定的本发明的精神及范围的情况下,在形式和细节上可以有多种变化。
已知炎症细胞会释出肿瘤坏死因子(TNF),特别是TNF-α,其造成多种细胞毒性反应、免疫反应及炎症反应。已知TNF-α涉及许多炎性疾病和自身免疫病的发生及延长,且当其被释放进入血液并全身作用时,会进一步导致严重的败血病和败血性休克。因为TNF-α是与活体的免疫系统广泛相关的因子,所以正在积极地开发TNF-α抑制剂。TNF-α以非活性形式被生物合成,并因受到蛋白酶的切割而变成活性形式;负责该活化的酶称作肿瘤坏死因子转化酶(TACE)。因此,抑制TACE的物质可治疗、改善或防止归因于TNF-α的疾病、病理状态、异常状态、困扰和不良症状等。
高迁移率族蛋白1(HMGB1)以高浓度存在于胸腺、淋巴结、睪丸中,以及胎儿肝脏中,并且除了肝细胞及脑细胞外,其通常存在于细胞核内。所述HMGB1蛋白具有由A-box、B-box及C-末端组成的3个结构域。
据Tracey等,1999报道,HMGB1蛋白扮演着炎症诱导性细胞因子的角色,且所述HMGB1的炎症诱导机制是:通过外部刺激物导致HMGB1乙酰化,其随后从细胞核移动进入细胞质。此后,已知其会被分泌至细胞外,或被分泌至坏死的细胞外(Bonaldi T等,EMBO J,(22)5551-60,2003)。
通过附图、以下实施例及实验来进一步描述本发明,所述附图、实施例及实验仅为了阐明本发明的特定实施方式,且无论如何都不应被解释为限制本发明的范围。
实施例1
PEP-1的合成以及对PEP-1(SEQ ID NO:1)的抗炎活性的测量
实验1:合成PEP-1(SEQ ID NO:1)
合成了由16个氨基酸组成的具有如下化学结构1的肽(PEP-1),该肽源自人类端粒酶,序列为SEQ ID NO:1:
<化学结构1>
SEQ ID NO:1(PEP-1)按照现有的固相肽合成方法合成。具体而言,通过Fmoc固相肽合成(SPPS)、使用ASP48S(Peptron,Inc.,Daejeon,ROK)从C-端偶联各氨基酸,由此合成肽。使用了下述肽(其C-端的第一个氨基酸附接至树脂):
NH2-Lys(Boc)-2-氯-三苯甲基树脂
NH2-Ala-2-氯-三苯甲基树脂
NH2-Arg(Pbf)-2-氯-三苯甲基树脂
用于合成肽的所有氨基酸材料在N-端都受到Fmoc保护,且氨基酸残基受到可溶于酸中的Trt、Boc、t-Bu(叔丁酯)、Pbf(2,2,4,6,7-五甲基二氢-苯并呋喃-5-磺酰基)的保护。例如:
Fmoc-Ala-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Pro-OH、Fmoc-Leu-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Trp(Boc)-OH、Fmoc-Met-OH、Fmoc-Asn(Trt)-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ahx-OH、Trt-巯基乙酸。
使用HBTU[六氟磷酸2-(1H-苯并三唑-1-基)-1,1,3,3-四甲基铵]/HOBt[N-羟基苯并三唑]/NMM[4-甲基吗啉]作为偶联试剂。在20%的DMF中,使用哌啶移除Fmoc。为了从残基上移除保护或为了将合成的肽与树脂分离,使用切割混合剂[TFA(三氟乙酸)/TIS(三异丙基硅烷)/EDT(乙二硫醇)/H2O=92.5/2.5/2.5/2.5]。
通过使用固相支架并重复以下过程来合成肽:氨基酸从氨基酸保护开始,使对应的氨基酸单独反应,用溶剂洗涤并除去保护。在从树脂上切下合成的肽之后,用HPLC进行纯化,并用MS验证合成状况,随后冷冻干燥。
PEP 1的具体合成过程描述如下。
1)偶联
将受NH2-Lys(Boc)-2-氯-三苯甲基树脂保护的氨基酸(8当量)和偶联剂HBTU(8当量)/HOBt(8当量)/NMM(16当量)熔融并加入DMF中,随后使其在室温下反应2小时,接着用DMF、MeOH和DMF依次进行洗涤。
2)Fmoc去保护
将20%的哌啶加入DMF中并于室温下进行2次为期5分钟的反应,接着用DMF、MeOH和DMF依次进行洗涤。
3)通过重复进行反应1和2来制造肽的基本骨架。
4)切割:将切割混合剂加入完全合成的肽中,将肽与树脂分离。
5)将冷却用乙醚加入所获得的混合物中,随后用离心来沉淀出所收集的肽。
6)在用制备型HPLC纯化之后,用LC/MS检查分子量,冻干以产生粉末形式。
实验2:PEP-1的抗炎活性测量
细胞系培养
在37℃和5%的CO2下,将来自韩国细胞库(Korea Cell Bank)的Raw 264.7巨噬细胞(KCBL,40071)维持在含有10%的胎牛血清(FBS;Gibco Laboratories)、100单位/mL的链霉素-青霉素(Gibco Laboratories)的达尔伯克改良的伊格尔培养基(DMEM;PAA,奥地利)中。以1×106个细胞/mL的密度将Raw 264.7细胞接种至96孔板中并温育过夜。
次日,用新鲜的培养基替换上述培养基,并将5μg/mL的肽(按实验实施例1的描述获得)加至细胞中。将细胞与肽温育30分钟后,加入50μL LPS(至1μg/mL的最终浓度),并将细胞再温育24小时。用1μg/mL脂多糖(LPS;Sigma,USA)处理诱导了炎症应答的实验样品,并用磷酸盐缓冲盐水(PBS;pH 7.2)处理对照样品。将来自每种条件的上清液样品收集于eppendorf管中,并执行进一步分析。
实验2-1:分析NO水平
使用Griess试剂系统(Promega,USA)测量Raw 264.7细胞(1×106个细胞/ml)中的一氧化氮(NO)水平。将50μl培养基加入96孔板,接着加入相同量的Griess试剂I(NED)溶液和Griess试剂II(对氨基苯磺酰胺溶液)。将细胞与这些试剂温育10分钟,之后,使用微孔板读取仪(Molecular Devices,USA)在30分钟内测量540nm下的光密度。使用亚硝酸钠标准曲线(0~100μM)来计算NO的浓度。
如下表3所示,以LPS刺激细胞增加了NO的表达,但在以LPS与PEP-1共同处理时,上述NO表达水平降低了。NO是在炎症期间产生的,且结果显示出PEP-1使NO水平减少至了对照的65%,这强力支持了PEP-1的抗炎效果。
表3:源自人类端粒酶的PEP 1的抗炎效果测量
实验2-2:对细胞因子抑制效果的分析
为了研究PEP-1对抑制促炎细胞因子产生的影响,以浓度为5μg/mL的PEP 1预先处理被浓度为1μg/mL的LPS激发的RAW 264.7细胞,将细胞再温育24小时。收集含有细胞培养基的上清液样品,并使用ELISA试剂盒(eBioscience,San Diego)分析细胞因子的水平。
在4℃下用100μL捕获抗体(在涂布缓冲液中稀释至制造商的操作规程所建议的浓度)涂布96孔板过夜。接着,在洗涤该板5次之后,每孔中加入200μL测定稀释液,并于室温下温育1小时以进行封闭。在用洗涤缓冲液洗涤各孔5次之后,将细胞培养物样品或每个细胞因子标准蛋白样品稀释,并在每孔中加入100μL各样品。在4℃下过夜温育含有样品的板。接着,在用洗涤缓冲液洗涤该板5次之后,加入100μL与抗生物素蛋白偶联的二抗,并在室温下温育1小时。
在与二抗温育之后,洗涤该板5次,并在室温下与100μL抗生物素蛋白-HRP(BDBioscience)温育30分钟。在洗涤该板7次之后,加入100μL TMB溶液(Pierce)并在室温下温育15分钟。在各孔中加入50μl 2N H2SO4来终止反应。使用微孔板读取仪测量450nm下的光密度。使用SPSS程序的ANOVA操作进行方差分析,从而进行统计学分析,并使用邓肯氏多变域检验法来验证分析之间的显著性。
实验2-3:IL-6分泌测量
如下表4所示,仅用LPS处理增加了细胞因子IL-6(白介素-6)的分泌。然而,用LPS与PEP-1共同处理显示出促炎细胞因子IL-6分泌水平的下降。更重要地,在用PEP-1处理后,促炎细胞因子的分泌水平下降了超过70%,这表明了PEP-1的强健的抗炎效果。
表4:PEP-1抑制细胞因子IL-6的产生
实验2-4:HMGB1、TNF-α、COX-2表达抑制
利用蛋白质印迹分析来确定蛋白表达水平。用PBS洗涤在含PEP-1培养基中生长的细胞,用0.05%的胰蛋白酶-EDTA处理,并离心收集细胞。将收集的细胞溶解在适当体积的裂解缓冲液中。通过离心使细胞内碎屑变为沉淀块,并利用SDS-聚丙烯酰胺凝胶电泳使来自各样品的等量蛋白分离。将分离的蛋白转移至硝化纤维膜(Schleicherand Schuell,Keene,NH,USA)上,接着测试对每种蛋白的抗体特异性。将膜与ECL(增强的化学发光)溶液(Amersham Life Science Corp.,Arlington Heights,IL,USA)一起温育;使其暴露于X光;并根据X光膜上显示的曝光程度来分析蛋白的表达水平。
进行蛋白质印迹分析来确定PEP-1对细胞因子蛋白表达的抑制效果。如下表5所示,以LPS刺激细胞增加了细胞因子的表达(HMGB1、TNF-α及COX)。然而,若用LPS和PEP-1同时处理细胞,上述促炎细胞因子的表达水平降低。结果显示,以PEP-1进行处理使促炎细胞因子水平下降了超过70%,这提供了有力的证据支持PEP-1的抗炎效果。
表5:PEP-1对促炎细胞因子的表达水平的抑制效果测量
实施例2
PEP RIA系列(SEQ ID NO:1~161)肽的TNF-α抑制效果
基于实施例1的结果(其中,SEQ ID NO:1(PEP1)具有TNF-α抑制效果),使用肽SEQID NO:1~161进行了实验,以确认它们的TNF-α抑制效果。肽SEQ ID NO:1~161的合成使用了与上述实施例1中相同的方法(用于合成PEP1的方法),但所添加的氨基酸不同。
实验1:细胞培养
使用Biocoll Separating Solution(Biochrom AG,Berlin,Germany)从收集自健康受试对象的血样(50ml)中分离出PBMC(外周血单个核细胞)层。将收集的PBMC在含有20%的人血清的RPMI 1640培养基中富集30分钟,接着将其转移到涂布有人血清的100mm聚苯乙烯细胞培养板上,并在37℃、5% CO2的温育器中温育2小时。使用冷的PBS使单核细胞从板底部脱离,并且在96孔板中用RPMI 1640培养基(补充有青霉素-链霉素100mg/ml;人血清20%)温育过夜,以达到1×105个细胞/孔的数量。
实验2:对源自PBMC的单核细胞中的TNF-α抑制效果的分析
进行了ELISA以查明PEP RIA系列肽如何影响TNF-α水平。在96孔板中温育源自PBMC的单核细胞以达到1×105个细胞/孔的数量,随后用LPS(脂多糖;10ng/ml,Sigma)处理2小时。向已用PBS洗涤了三次的单核细胞中加入OPTI-MEM培养基以诱导细胞饥饿1小时,取4μM肽并温育2小时。存在三个阴性对照组。第一组未经任何处理。第二组用雌激素处理过(在本实验中,使用雌二醇作为一种雌激素)。第三组用LPS(10ng/ml)或用LPS(10ng/ml)+雌激素(20nM)处理过。已确认具有TNF-α抑制活性的PEP1被用作阳性对照来测量TNF-α抑制活性。温育后,遵循ELISA试剂盒手册(R&D,Minneapolis,MN,USA)测量TNF-α。定量方法的细节可参见实施例1的实验2.2。
使用上述方法,筛选出了具有TNF-α抑制效果的肽。用内毒素LPS(10ng/ml)刺激源自PBMC的单核细胞2小时,并添加OPTI-MEM诱导细胞饥饿1小时,接着用4μM的161种肽处理和温育2小时。使用ELISA测量细胞培养基中的TNF-α量,并通过与阴性对照和阳性对照进行比较来筛选出具有TNF-α抑制效果的肽(图1至图16)。
以下肽与仅用LPS处理的对照组相比显示出了TNF-α抑制效果:SEQ ID NO:1~SEQID NO:6、SEQ ID NO:9、SEQ ID NO:11、SEQ ID NO:14~21、SEQ ID NO:23~SEQ ID NO:37、SEQ ID NO:39~SEQ ID NO:44、SEQ ID NO:47~SEQ ID NO:53、SEQ ID NO:55~SEQ IDNO:61、SEQ ID NO:63~SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:94、SEQ ID NO:96、SEQID NO:99~SEQ ID NO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ ID NO:115、SEQ ID NO:116、SEQ ID NO:120~SEQ ID NO:122、SEQ ID NO:124、SEQ ID NO:129~SEQ ID NO:133、SEQ ID NO:142~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149和SEQID NO:155~SEQ ID NO:159。
此外,以下肽与用LPS+雌激素处理的组相比显示出了TNF-α抑制效果:SEQ ID NO:15~SEQ ID NO:18、SEQ ID NO:23~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:31~SEQ IDNO:34、SEQ ID NO:39~SEQ ID NO:41、SEQ ID NO:47、SEQ ID NO:48、SEQ ID NO:51~SEQID NO:53、SEQ ID NO:55~SEQ ID NO:58、SEQ ID NO:61、SEQ ID NO:65~SEQ ID NO:68、SEQ ID NO:70、SEQ ID NO:73~SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:87、SEQ ID NO:90~SEQ ID NO:94、SEQ ID NO:96、SEQ ID NO:99、SEQ IDNO:101~SEQ IDNO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ ID NO:120、SEQ ID NO:121、SEQ ID NO:129~SEQ ID NO:132、SEQ ID NO:142~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149和SEQ ID NO:157~SEQ ID NO:159。
实验3:对影响THP1细胞系中的TNF-α水平的肽的分析
使用人类急性单核细胞性白血病细胞系THP-1(美国典型培养物保藏中心(ATCC)(Manassas,VA,USA))进行了实验。
在96孔板中用RPMI 1640培养基温育THP-1细胞24小时以达到1×105个细胞/孔的数量,随后添加100μM PMA(12-肉豆蔻酸-13-乙酸佛波醇酯)以分化成巨噬细胞。在用PMA使THP-1分化1天成为巨噬细胞后,用LPS处理2小时并洗去。饥饿1小时,随后用PEP1进行处理。
用LPS(脂多糖;10ng/ml,Sigma)处理在PMA下分化的THP-1细胞2小时,随后用PBS洗涤2次。向细胞中添加OPTI-MEM培养基以诱导细胞饥饿1小时,接着取1μM的161种肽并温育1小时。温育后,使用ELISA试剂盒测量TNF-α水平,并筛选出使TNF-α水平下降的肽(图17至图35)。
结果显示,与仅用LPS处理的对照组相比,肽SEQ ID NO:1~SEQ ID NO:5、SEQ IDNO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ IDNO:17~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:32~SEQ ID NO:53、SEQID NO:55~SEQ ID NO:60、SEQ ID NO:67、SEQ ID NO:68、SEQ ID NO:70、SEQ ID NO:72~SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:92、SEQ ID NO:94、SEQ ID NO:99~SEQ ID NO:112、SEQ ID NO:114、SEQ ID NO:127~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149、SEQ ID NO:151和SEQ ID NO:153~SEQ ID NO:161看上去能够降低TNF-α水平。
此外,与用LPS+雌激素(LPS+e)处理的组相比,选择SEQ ID NO:1~SEQ ID NO:5、SEQ ID NO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ ID NO:17~SEQ ID NO:23、SEQ ID NO:25~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:33~SEQ ID NO:43、SEQ ID NO:156、SEQ ID NO:157和SEQ ID NO:159作为降低TNF-α表达水平的肽。
实施例3
肽(SEQ ID NO:1~161)对由淀粉样-β蛋白引起的炎症的影响
HMGB1先经历乙酰化,并因外部刺激而移位至细胞质中。随后其被分泌至细胞外,因而扮演着致炎性细胞因子的角色。因为当此活性引起炎症时,HMGB1蛋白被分泌至细胞外,且炎性疾病(例如Churg strauss综合征、类风湿性关节炎和舍格伦综合征)患者将呈现出升高的HMGB1血清水平。因此,如果即使在致炎刺激物存在时细胞核仍含有大量的HMGB1,则揭示了HMGB1未被分泌至细胞外的事实,这意味着炎症受到了抑制。
实验1:细胞培养
在用多聚L-赖氨酸(Sigma,Saint Louis,MO,USA)预先涂布的100mm盘(Corning,PA,USA)上,在包含10%热失活马血清、5%热失活胎牛血清、100单位/ml青霉素和100g/ml链霉素的RPMI 1640培养基(GIBCO,Grand Island,NY,USA)中,使未分化的PC12细胞(ATCC,Rockville,MD,USA)保持在对数生长期。在含有5% CO2的潮湿气氛中于37℃下温育培养物。使培养物生长至50%融合,将其收集在不含Ca2+/Mg2+的含有1mM EDTA的Hank氏平衡盐溶液中。将细胞以1×106个细胞/100mm盘的密度铺板,并温育24小时。为了进行神经元分化,使PC12细胞血清饥饿12小时(包含100单位/ml青霉素和100g/ml链霉素但不含马血清或胎牛血清的RPMI 1640培养基);之后,将细胞保持在无血清培养基中。两天后,将培养基更换为新鲜的无血清培养基。第三天,将NGF(50ng/ml,Sigma,Saint Louis,MO,USA)添加至培养基中,将培养物再保持三天。分化后,将nPC12细胞与20μM淀粉样β蛋白以及各种浓度的肽[0(对照)、1、10和50μM]一起温育48小时。
实验2.蛋白质印迹分析
通过蛋白质印迹分析了HMGB1的水平。简言之,用冷的PBS洗涤5×106个细胞两次,在裂解缓冲液[50mM Tris(pH 8.0),150mM NaCl,0.02%叠氮化钠,0.2% SDS,100μg/ml苯基甲基磺酰氟(PMSF),50μl/ml抑肽酶,1% Igepal 630,100mM NaF,0.5%脱氧胆酸钠,0.5mM EDTA,0.1mM EGTA]中于冰上温育10分钟;在2000×g下离心10分钟以使未破碎的细胞和细胞核变为沉淀块,并在10,000×g下离心以使裂解物澄清。所使用的抗体为:抗HMGB1(1:1000,Cell Signaling,Beverly,MA,USA)和抗β-微管蛋白(1:1000,Cell Signaling,Beverly,MA,USA)。用包含0.05% Tween-20(TBST)的Tris缓冲盐水洗涤膜,随后使用与HRP偶联的抗兔抗体(Amersham Pharmacia Biotech,Piscataway,NJ,USA)进行处理,而后进行ECL检测(Amersham Pharmacia Biotech)。用图像分析仪(GE Healthcare,ImageQuant LAS4000)对印迹进行定量。
作为蛋白质印迹分析的结果,选出了显示出HMGB1在细胞中积累的肽。图36至图108是选出的肽的蛋白质印迹结果。这些图中的微管蛋白用于确认蛋白表达。所选的肽的序列如下:
SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:4、SEQ ID NO:6、SEQ ID NO:7、SEQ IDNO:8、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:14、SEQ ID NO:15、SEQ IDNO:17、SEQ ID NO:18、SEQ ID NO:20、SEQ ID NO:22、SEQ ID NO:23、SEQ ID NO:24、SEQ IDNO:25、SEQ ID NO:26、SEQ ID NO:27、SEQ ID NO:28、SEQ ID NO:29、SEQ ID NO:30、SEQ IDNO:33、SEQ ID NO:34、SEQ ID NO:35、SEQ ID NO:36、SEQ ID NO:37、SEQ ID NO:38、SEQ IDNO:39、SEQ ID NO:40、SEQ ID NO:41、SEQ ID NO:42、SEQ ID NO:44、SEQ ID NO:45、SEQ IDNO:52、SEQ ID NO:57、SEQ ID NO:60、SEQ ID NO:61、SEQ ID NO:62、SEQ ID NO:64、SEQ IDNO:65、SEQ ID NO:67、SEQ ID NO:68、SEQ ID NO:69、SEQ ID NO:91、SEQ ID NO:99、SEQ IDNO:100、SEQ ID NO:104、SEQ ID NO:106、SEQ ID NO:107、SEQ ID NO:108、SEQ ID NO:109、SEQ ID NO:111、SEQ ID NO:112、SEQ ID NO:115、SEQ ID NO:117、SEQ ID NO:118、SEQ IDNO:119、SEQ ID NO:120、SEQ ID NO:122、SEQ ID NO:124、SEQ ID NO:125、SEQ ID NO:126、SEQ ID NO:129、SEQ ID NO:130、SEQ ID NO:131、SEQ ID NO:132、SEQ ID NO:135、SEQ IDNO:146、SEQ ID NO:151、SEQ ID NO:154和SEQ ID NO:156。
Claims (14)
1.一种具有抗炎活性的肽,其中,所述肽由选自SEQ ID NO:1~SEQ ID NO:70、SEQ IDNO:72~SEQ ID NO:100、SEQ ID NO:102~SEQ ID NO:128和SEQ ID NO:130~SEQ ID NO:161的一条氨基酸序列构成。
2.如权利要求1所述的肽,其中,所述肽由选自由SEQ ID NO:1~SEQ ID NO:6、SEQ IDNO:9、SEQ ID NO:11、SEQ ID NO:14~SEQ ID NO:21、SEQ ID NO:23~SEQ ID NO:37、SEQID NO:39~SEQ ID NO:44、SEQ ID NO:47~SEQ ID NO:53、SEQ ID NO:55~SEQ ID NO:61、SEQ ID NO:63~SEQ ID NO:70、SEQ ID NO:72~SEQ ID NO:82、SEQ ID NO:84~SEQ IDNO:94、SEQ ID NO:96、SEQ ID NO:99、SEQ ID NO:100、SEQ ID NO:102~SEQ ID NO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ ID NO:115、SEQ ID NO:116、SEQ ID NO:120~SEQID NO:122、SEQ ID NO:124、SEQ ID NO:130~SEQ ID NO:133、SEQ ID NO:142~SEQ IDNO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149和SEQ ID NO:155~SEQ ID NO:159组成的组的任一条氨基酸序列构成。
3.如权利要求2所述的肽,其中,所述肽由选自由SEQ ID NO:15~SEQ ID NO:18、SEQID NO:23~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:31~SEQ ID NO:34、SEQ ID NO:39~SEQ ID NO:41、SEQ ID NO:47、SEQ ID NO:48、SEQ ID NO:51~SEQ ID NO:53、SEQ ID NO:55~SEQ ID NO:58、SEQ ID NO:61、SEQ ID NO:65~SEQ ID NO:68、SEQ ID NO:70、SEQ IDNO:73~SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:87、SEQID NO:90~SEQ ID NO:94、SEQ ID NO:96、SEQ ID NO:99、SEQ ID NO:102~SEQ ID NO:104、SEQ ID NO:107~SEQ ID NO:109、SEQ ID NO:120、SEQ ID NO:121、SEQ ID NO:130~SEQ ID NO:132、SEQ ID NO:142~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ IDNO:149和SEQ ID NO:157~SEQ ID NO:159组成的组的任一条氨基酸序列构成。
4.如权利要求1所述的肽,其中,所述肽由选自由SEQ ID NO:1~SEQ ID NO:5、SEQ IDNO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ IDNO:17~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:32~SEQ ID NO:53、SEQID NO:55~SEQ ID NO:60、SEQ ID NO:67、SEQ ID NO:68、SEQ ID NO:70、SEQ ID NO:72~SEQ ID NO:82、SEQ ID NO:84~SEQ ID NO:92、SEQ ID NO:94、SEQ ID NO:99~SEQ ID NO:100、SEQ ID NO:102~SEQ ID NO:112、SEQ ID NO:114、SEQ ID NO:127、SEQ ID NO:128、SEQ ID NO:130~SEQ ID NO:144、SEQ ID NO:146、SEQ ID NO:148、SEQ ID NO:149、SEQ IDNO:151和SEQ ID NO:153~SEQ ID NO:161组成的组的任一条氨基酸序列构成。
5.如权利要求4所述的肽,其中,所述肽由选自由SEQ ID NO:1~SEQ ID NO:5、SEQ IDNO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:15、SEQ IDNO:17~SEQ ID NO:23、SEQ ID NO:25~SEQ ID NO:27、SEQ ID NO:29、SEQ ID NO:30、SEQID NO:33~SEQ ID NO:43、SEQ ID NO:156、SEQ ID NO:157和SEQ ID NO:159组成的组的任一条氨基酸序列构成。
6.如权利要求1所述的肽,其中,所述肽由选自由SEQ ID NO:1、SEQ ID NO:2、SEQ IDNO:4、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:12、SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:20、SEQ IDNO:22、SEQ ID NO:23、SEQ ID NO:24、SEQ ID NO:25、SEQ ID NO:26、SEQ ID NO:27、SEQ IDNO:28、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:33、SEQ ID NO:34、SEQ ID NO:35、SEQ IDNO:36、SEQ ID NO:37、SEQ ID NO:38、SEQ ID NO:39、SEQ ID NO:40、SEQ ID NO:41、SEQ IDNO:42、SEQ ID NO:44、SEQ ID NO:45、SEQ ID NO:52、SEQ ID NO:57、SEQ ID NO:60、SEQ IDNO:61、SEQ ID NO:62、SEQ ID NO:64、SEQ ID NO:65、SEQ ID NO:67、SEQ ID NO:68、SEQ IDNO:69、SEQ ID NO:91、SEQ ID NO:99、SEQ ID NO:100、SEQ ID NO:104、SEQ ID NO:106、SEQID NO:107、SEQ ID NO:108、SEQ ID NO:109、SEQ ID NO:111、SEQ ID NO:112、SEQ ID NO:115、SEQ ID NO:117、SEQ ID NO:118、SEQ ID NO:119、SEQ ID NO:120、SEQ ID NO:122、SEQID NO:124、SEQ ID NO:125、SEQ ID NO:126、SEQ ID NO:130、SEQ ID NO:131、SEQ ID NO:132、SEQ ID NO:135、SEQ ID NO:146、SEQ ID NO:151、SEQ ID NO:154和SEQ ID NO:156组成的组的任一条氨基酸序列构成。
7.如权利要求1~6中任一项所述的肽,所述肽源自人类端粒酶。
8.一种多核苷酸,所述多核苷酸编码权利要求1~6中任一项所述的肽。
9.肽在制备抗炎组合物中的应用,其中,所述肽为权利要求1~6中任一项所述的肽,所述炎是能够通过抑制TNF-α而治疗的炎。
10.如权利要求9所述的应用,其中,所述组合物用于改善炎性疾病。
11.如权利要求9所述的应用,其中,所述组合物为用于改善皮肤炎症的化妆品组合物。
12.如权利要求9所述的应用,其中,所述组合物为用于改善炎性疾病的药物组合物。
13.如权利要求9所述的应用,其中,所述组合物为用于改善炎症的食品组合物。
14.肽在制备用于治疗能够通过抑制TNF-α而治疗的炎性疾病的试剂盒中的应用,所述试剂盒包含:权利要求1~6中任一项所述的肽;以及包括所述肽的施用剂量、施用途径、施用频率和适应证中的至少一种的使用说明书。
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0079096 | 2012-07-20 | ||
KR1020120079096A KR20140012385A (ko) | 2012-07-20 | 2012-07-20 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물 |
KR10-2012-0089162 | 2012-08-14 | ||
KR10-2012-0089161 | 2012-08-14 | ||
KR1020120089167A KR20140022699A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
KR20120089161 | 2012-08-14 | ||
KR10-2012-0089167 | 2012-08-14 | ||
KR1020120089162A KR20140022698A (ko) | 2012-08-14 | 2012-08-14 | 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물 |
KR20120104144 | 2012-09-19 | ||
KR10-2012-0104207 | 2012-09-19 | ||
KR20120104207 | 2012-09-19 | ||
KR10-2012-0104144 | 2012-09-19 | ||
PCT/EP2013/055326 WO2014012683A1 (en) | 2012-07-20 | 2013-03-15 | Anti-inflammatory peptides and composition comprising the same |
CN201380038045.1A CN104470947B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽及包含其的组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380038045.1A Division CN104470947B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽及包含其的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117551631A true CN117551631A (zh) | 2024-02-13 |
Family
ID=47882177
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380038045.1A Active CN104470947B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽及包含其的组合物 |
CN202311502816.XA Pending CN117551631A (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 |
CN201910110866.0A Active CN109777791B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380038045.1A Active CN104470947B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽及包含其的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910110866.0A Active CN109777791B (zh) | 2012-07-20 | 2013-03-15 | 抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 |
Country Status (8)
Country | Link |
---|---|
US (6) | US20150125438A1 (zh) |
EP (3) | EP3896078A1 (zh) |
JP (6) | JP6352911B2 (zh) |
KR (2) | KR102302392B1 (zh) |
CN (3) | CN104470947B (zh) |
ES (2) | ES2693321T3 (zh) |
TW (4) | TWI779287B (zh) |
WO (1) | WO2014012683A1 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150014483A (ko) | 2012-05-11 | 2015-02-06 | 주식회사 카엘젬백스 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
WO2014010971A1 (ko) | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
EP3736282B1 (en) | 2012-09-19 | 2023-06-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
CN107312759A (zh) | 2012-09-19 | 2017-11-03 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
SG10201601929YA (en) * | 2013-03-15 | 2016-04-28 | Promega Corp | Activation Of Bioluminescence By Structural Complementation |
US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
WO2015005723A1 (ko) * | 2013-07-12 | 2015-01-15 | 주식회사 카엘젬백스 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
EP3072519B1 (en) | 2013-11-22 | 2020-08-19 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
EP3085380B1 (en) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
US9937240B2 (en) * | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
JP6466971B2 (ja) * | 2014-04-30 | 2019-02-06 | ジェムバックス アンド カエル カンパニー,リミティド | 臓器、組織又は細胞移植用組成物、キット及び移植方法 |
WO2016042131A1 (en) * | 2014-09-18 | 2016-03-24 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
KR101662438B1 (ko) * | 2015-04-07 | 2016-10-04 | 가톨릭대학교 산학협력단 | X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물 |
KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
EP3305802B1 (en) | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
KR102638286B1 (ko) * | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
CN108350033A (zh) | 2015-08-28 | 2018-07-31 | 威斯康星州医药大学股份有限公司 | 端粒酶易位的肽抑制剂及其治疗用途 |
AU2016321333A1 (en) * | 2015-09-09 | 2018-04-26 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health |
KR20180123512A (ko) * | 2016-04-07 | 2018-11-16 | 주식회사 젬백스앤카엘 | 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
KR101887577B1 (ko) | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
US11339191B2 (en) * | 2016-12-22 | 2022-05-24 | Universite De Montpellier | Stapled peptides and uses thereof |
JP6601848B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
JP6601849B2 (ja) * | 2017-08-21 | 2019-11-06 | 株式会社大一商会 | 遊技機 |
KR102092843B1 (ko) * | 2018-08-30 | 2020-03-24 | 충남대학교 산학협력단 | 암 예방 또는 치료용 펩타이드 및 이의 용도 |
KR102274658B1 (ko) * | 2018-11-16 | 2021-07-09 | 주식회사 카인사이언스 | 염증성 피부질환 치료용 펩타이드 및 이의 용도 |
KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
KR102146937B1 (ko) * | 2018-12-11 | 2020-08-21 | 대한민국 | 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물 |
KR102266613B1 (ko) * | 2020-09-21 | 2021-06-18 | 자안바이오 주식회사 | 항염증 활성을 갖는 신규한 펩티드 및 이의 용도 |
EP4288149A1 (en) * | 2021-02-08 | 2023-12-13 | Bacoba AG | Treatment of skin disorders |
WO2023214802A1 (ko) * | 2022-05-03 | 2023-11-09 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
DE69534568T2 (de) * | 1994-07-07 | 2006-07-27 | Geron Corp., Menlo Park | Säugetier-telomerase |
AU716376B2 (en) * | 1996-06-25 | 2000-02-24 | Pfizer Inc. | Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
WO1998014592A2 (en) * | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
CN1270634A (zh) * | 1997-07-01 | 2000-10-18 | 卡姆比亚生物系统有限责任公司 | 脊椎动物端粒酶基因和蛋白质及其用途 |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US20030171280A1 (en) * | 2001-07-31 | 2003-09-11 | Soderstrom Karl Petter | Compositions and methods for modulation of immune responses |
JP2005502335A (ja) * | 2001-08-08 | 2005-01-27 | インサイト・ゲノミックス・インコーポレイテッド | 細胞成長、分化および細胞死関連タンパク質 |
US8492438B2 (en) * | 2002-04-26 | 2013-07-23 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
CA2524912A1 (en) * | 2003-05-01 | 2004-11-18 | Musc Foundation For Research Development | An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells |
CN101011571A (zh) * | 2006-03-13 | 2007-08-08 | 上海交通大学医学院 | GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用 |
CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
ES2376010T3 (es) * | 2006-10-12 | 2012-03-08 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma. |
AU2008252628A1 (en) | 2007-05-18 | 2008-11-27 | Inhibox Ltd. | Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents |
WO2009025871A1 (en) * | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
HUE030984T2 (en) * | 2008-06-16 | 2017-06-28 | Mediolanum Farm S P A | Antitumor immunotherapy |
US8252282B2 (en) * | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
WO2010032322A1 (ja) | 2008-09-22 | 2010-03-25 | 日清ファルマ株式会社 | 抗炎症性ペプチド |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
EP2536830B1 (en) * | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
KR20150014483A (ko) | 2012-05-11 | 2015-02-06 | 주식회사 카엘젬백스 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
EP3736282B1 (en) | 2012-09-19 | 2023-06-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
CN107312759A (zh) | 2012-09-19 | 2017-11-03 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
KR102201430B1 (ko) | 2012-09-19 | 2021-01-12 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
US10383926B2 (en) * | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
WO2015005723A1 (ko) | 2013-07-12 | 2015-01-15 | 주식회사 카엘젬백스 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
EP3305802B1 (en) | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
WO2017066349A1 (en) | 2015-10-13 | 2017-04-20 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
-
2013
- 2013-03-05 US US14/400,322 patent/US20150125438A1/en not_active Abandoned
- 2013-03-15 KR KR1020207019525A patent/KR102302392B1/ko active IP Right Grant
- 2013-03-15 KR KR1020147034319A patent/KR20150031413A/ko active Application Filing
- 2013-03-15 ES ES13709221T patent/ES2693321T3/es active Active
- 2013-03-15 CN CN201380038045.1A patent/CN104470947B/zh active Active
- 2013-03-15 JP JP2015521997A patent/JP6352911B2/ja active Active
- 2013-03-15 CN CN202311502816.XA patent/CN117551631A/zh active Pending
- 2013-03-15 CN CN201910110866.0A patent/CN109777791B/zh active Active
- 2013-03-15 ES ES18187426T patent/ES2871899T3/es active Active
- 2013-03-15 EP EP21162575.1A patent/EP3896078A1/en active Pending
- 2013-03-15 EP EP13709221.9A patent/EP2875042B1/en active Active
- 2013-03-15 EP EP18187426.4A patent/EP3428182B1/en active Active
- 2013-03-15 WO PCT/EP2013/055326 patent/WO2014012683A1/en active Application Filing
- 2013-05-01 TW TW109115548A patent/TWI779287B/zh active
- 2013-05-01 TW TW108101145A patent/TWI700290B/zh active
- 2013-05-01 TW TW106121753A patent/TWI647311B/zh active
- 2013-05-01 TW TW102115615A patent/TWI658141B/zh active
-
2017
- 2017-04-05 US US15/479,746 patent/US20170275603A1/en not_active Abandoned
- 2017-04-10 JP JP2017077422A patent/JP6514259B2/ja active Active
-
2019
- 2019-04-11 JP JP2019075635A patent/JP6788062B2/ja active Active
-
2020
- 2020-01-17 US US16/746,018 patent/US20200140832A1/en not_active Abandoned
- 2020-03-13 US US16/818,001 patent/US11098294B2/en active Active
- 2020-10-29 JP JP2020181780A patent/JP7128246B2/ja active Active
-
2021
- 2021-07-30 US US17/389,671 patent/US11905536B2/en active Active
-
2022
- 2022-08-18 JP JP2022130519A patent/JP7440581B2/ja active Active
-
2024
- 2024-01-12 US US18/411,838 patent/US20240158768A1/en active Pending
- 2024-02-15 JP JP2024021407A patent/JP2024056904A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109777791B (zh) | 抗炎性肽、其编码多核苷酸及其在制备抗炎组合物和试剂盒中的应用 | |
US11622998B2 (en) | Anti-inflammatory peptides and composition comprising the same | |
KR102307567B1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
TWI836435B (zh) | 抗發炎胜肽及包含其之成分 | |
TW202417463A (zh) | 抗發炎胜肽及包含其之成分(二) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |